Sandoz obtained EC approval for infliximab biosimilar

| By | Drug Quality Control, Sandoz
0
220

Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.

Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn’s disease, pediatric Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

The EC approval was based on review of a comprehensive development program, including analytical, preclinical and clinical data, which confirmed Zessly matched its reference medicine in terms of safety, efficacy and quality. The clinical Phase III confirmatory study in rheumatoid arthritis met its primary endpoint, demonstrating equivalent efficacy of Zessly to the reference medicine as measured by the American College of Rheumatology 20 (ACR20) response at Week 14.

As a Novartis division, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization. Zessly is the sixth approved biosimilar medicine for Sandoz, with several more major oncology and immunology launches expected globally by 2020.

SOURCE: sandoz
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.